Video
Dr. Dason on “not favoring” treatments for UTUC patients post-nephroureterectomy
Author(s):
“Multidisciplinary discussion is best,” says Shawn Dason, MD, FRCSC.
Video Player is loading.
In this video, Shawn Dason, MD, FRCSC, discusses the takeaways of the study, “How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?” This study was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus
Related Videos
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
